Harborside


PharmaCielo Ltd.

CVE: PCLO


Canadian symbol: PCLO.V
US symbol: PCLOF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 58.95M
Enterprise Value 67.76M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)14.04
Price/Book (mrq)4.17
Enterprise Value/Revenue 16.35
Enterprise Value/EBITDA -4.01

Trading Information

Stock Price History

Beta (5Y Monthly) 2.84
52-Week Change 3-69.29%
S&P500 52-Week Change 3-16.88%
52 Week High 31.4800
52 Week Low 30.3350
50-Day Moving Average 30.4493
200-Day Moving Average 30.6656

Share Statistics

Avg Vol (3 month) 362.87k
Avg Vol (10 day) 349.64k
Shares Outstanding 5151.16M
Implied Shares Outstanding 6N/A
Float 8145.88M
% Held by Insiders 13.54%
% Held by Institutions 15.85%
Shares Short (Sept 14, 2022) 465.35k
Short Ratio (Sept 14, 2022) 41.81
Short % of Float (Sept 14, 2022) 4N/A
Short % of Shares Outstanding (Sept 14, 2022) 40.04%
Shares Short (prior month Aug 14, 2022) 4121.73k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan 17, 2019
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-427.94%

Management Effectiveness

Return on Assets (ttm)-30.32%
Return on Equity (ttm)-89.43%

Income Statement

Revenue (ttm)4.14M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)375.10%
Gross Profit (ttm)-4.17M
EBITDA -17.55M
Net Income Avi to Common (ttm)-19.29M
Diluted EPS (ttm)-0.1550
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.17M
Total Cash Per Share (mrq)0.01
Total Debt (mrq)9.98M
Total Debt/Equity (mrq)70.55
Current Ratio (mrq)0.81
Book Value Per Share (mrq)0.09

Cash Flow Statement

Operating Cash Flow (ttm)-16.46M
Levered Free Cash Flow (ttm)-12.38M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
PCLO.V
PharmaCielo
1 week ago
PCLO.V
PharmaCielo
1 month ago
PCLO.V
PharmaCielo
1 month ago
PCLO.V
PharmaCielo
1 month ago
PCLO.V
PharmaCielo
3 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
8 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
10 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
2 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago
PCLO.V
PharmaCielo
3 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPS-0.16-0.05N/AN/A
Revenue EstimateCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
No. of Analysts1111
Avg. EstimateN/A3.3MN/A23.42M
Low Estimate1.18M3.3M2.82M23.42M
High Estimate1.18M3.3M2.82M23.42M
Year Ago Sales881k675k2.65MN/A
Sales Growth (year/est)N/A388.90%N/AN/A
Earnings History2020-12-302021-03-302021-06-292021-09-29
EPS Est.0.020.05-0.03-0.03
EPS Actual-0.16-0.05-0.04-0.06
Difference-0.18-0.1-0.01-0.03
Surprise %-900.00%-200.00%-33.30%-100.00%
EPS TrendCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
Current Estimate0000
7 Days Ago-0.03-0.02-0.13-0.05
30 Days Ago-0.03-0.02-0.13-0.05
60 Days Ago-0.03-0.02-0.13-0.05
90 Days Ago-0.03-0.02-0.13-0.05
EPS RevisionsCurrent Qtr. (Dec 2021)Next Qtr. (Mar 2022)Current Year (2021)Next Year (2022)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPCLO.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
3.54%% of Shares Held by All Insider
5.85%% of Shares Held by Institutions
6.07%% of Float Held by Institutions
3Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
AdvisorShares Investments, LLC364,861Mar 30, 20220.24%142,295

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Wasatch Microcap Fund7,995,671Jun 29, 20225.29%3,118,311
ETF Series Solutions-Defiance Next Gen Altered Experience ETF494,370Jun 29, 20220.33%192,804
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF361,137Aug 30, 20220.24%140,843
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PharmaCielo Ltd.


PharmaCielo Announces Shipment of Dried Cannabis Flower to the Czech Republic, Representing the Company's First Shipment of Medicinal Grade Dried Cannabis Flower into the EU

PharmaCielo Announces Shipment of Dried Cannabis Flower to the Czech Republic, Representing the Company’s First Shipment of Medicinal Grade Dried Cannabis Flower into the EU

Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoids TORONTO and RIONEGRO, Colombia, Sept. 15, 2022 - PharmaCielo Ltd. ("PharmaCielo") ( TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of ... Read More...
PharmaCielo Announces Receipt of Production Quota of THC Dominant Dried Cannabis Flower for Export

PharmaCielo Announces Receipt of Production Quota of THC Dominant Dried Cannabis Flower for Export

Colombian government has maintained its commitment to supporting its cannabis producers and building a dominant global export industry. Five tonne quota to grow THC-dominant cannabis strains for export as dried flower will support the fulfillment of current sales agreements, beginning in early 2023. TORONTO and RIONEGRO, Colombia, Sept... Read More...
PharmaCielo Announces Q2 2022 Financial Results; Upsizes Oversubscribed Debenture Financing

PharmaCielo Announces Q2 2022 Financial Results; Upsizes Oversubscribed Debenture Financing

The Company continues to grow sales and expects to build momentum through the remainder of 2022 and through 2023, with recent progress in Israel, Brazil and Mexico. PharmaCielo product has been sold in 14 countries to date, and the Company expects to increase this total to 17 countries by the end of 2022. PharmaCielo's previously announc... Read More...
PharmaCielo Announces Receipt of ICANN G.A.P and GACP Certifications, Opening Commercial Access to the Israeli Market

PharmaCielo Announces Receipt of ICANN G.A.P and GACP Certifications, Opening Commercial Access to the Israeli Market

The Company expects to begin exporting dried flower to Israel in early 2023. Israel is one of the largest importers of medical cannabis in the world, with 109,352 active medical patients in 2021 (+35% vs. 2020)1. TORONTO and RIONEGRO, Colombia, Aug. 25, 2022 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian p... Read More...
PharmaCielo Announces First Shipment to Mexican Joint Venture Partner

PharmaCielo Announces First Shipment to Mexican Joint Venture Partner

The Company has made a pre-commercial shipment of CBD isolate to its Mexican joint venture, to support product development by a Mexican phytotherapeutic company. TORONTO and RIONEGRO, Colombia , Aug. 4, 2022 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer ... Read More...
PharmaCielo Announces Sales Agreement with Brazilian Phyto-Therapeutic Customer, and Key Management and Board Appointments

PharmaCielo Announces Sales Agreement with Brazilian Phyto-Therapeutic Customer, and Key Management and Board Appointments

TORONTO and RIONEGRO, Colombia , July 28, 2022 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced a supply agreement (the "Agreement") with... Read More...
PharmaCielo Announces Shipment of CBD Full Spectrum Oil to a Brazilian Pharmaceutical Customer

PharmaCielo Announces Shipment of CBD Full Spectrum Oil to a Brazilian Pharmaceutical Customer

The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market. TORONTO and RIONEGRO, Colombia, June 6, 2022 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and p... Read More...
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2022

PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2022

The Company expects Revenue to continue to grow – recently shipped 300 kg of CBD Full Spectrum Oil to a Spanish pharmaceutical company, announced entrance into Polish market, and shipments to Germany expected by late 2022. Steadily building pipeline in other key markets. Continued progress on streamlining the business, while continuing t... Read More...
PharmaCielo Enters Spanish Market with Initial Shipment of 300 kg of CBD Full Spectrum Oil to Pharmaceutical Company

PharmaCielo Enters Spanish Market with Initial Shipment of 300 kg of CBD Full Spectrum Oil to Pharmaceutical Company

The Company has shipped pharmaceutical grade CBD full spectrum oil containing THC to Extractions Solutions SL, to support pre-commercial development of a full spectrum product for the European market. TORONTO and RIONEGRO, COLOMBIA, May 24, 2022 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadia... Read More...
PharmaCielo Provides Update on Non-Brokered Private Placement of Debenture Units

PharmaCielo Provides Update on Non-Brokered Private Placement of Debenture Units

TORONTO and RIONEGRO, Colombia, May 11, 2022 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), announces today that, further to its previously announced non-brokered priva... Read More...
PharmaCielo partners with Soteria Holdings Limited to license, import and wholesale its medical cannabis flower and extracts in the Polish market

PharmaCielo partners with Soteria Holdings Limited to license, import and wholesale its medical cannabis flower and extracts in the Polish market

Poland is one of the largest cannabis markets in Europe by patient population, with more than 28,000 prescriptions issued to approximately 10,000 patients in the first nine months of 20211. The Company expects to begin shipping to Poland during the first half of 2023. TORONTO and RIONEGRO, Colombia, May 6, 2022 - PharmaCielo Ltd. ("Phar... Read More...
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2021

PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2021

Regulation to enable dried flower export and expand applications of CBD-based products passed by the Colombian Government on February 22, 2022 PharmaCielo's upstream and downstream scale and quality uniquely position the Company to be a dominant competitor with current suppliers of psychoactive flower to the EU and other markets. Executi... Read More...
Colombian Government Provides Final Commercial Guidelines Related to the Export of Dried Flower

Colombian Government Provides Final Commercial Guidelines Related to the Export of Dried Flower

Builds on the passing of Regulation 227 in February, which implemented legal provisions to enable dried flower export and access to additional opportunities for CBD-based products. PharmaCielo expects to begin exporting dried flower in the second quarter of 2022, with volumes growing through the remainder of the year. TORONTO and RIONEG... Read More...
PharmaCielo Signs Sales Agreement with Greenstein to Supply THC Final Products that will be Commercialized through NOWEDA, a Pharmaceutical Wholesaler to all Pharmacies Across Germany

PharmaCielo Signs Sales Agreement with Greenstein to Supply THC Final Products that will be Commercialized through NOWEDA, a Pharmaceutical Wholesaler to all Pharmacies Across Germany

The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo's first sales agreement related to THC products. Represents a significant milestone related to management's re-focusing of PharmaCielo's product strategy toward THC-dominant p... Read More...
PharmaCielo Provides Update on Latin American Sales Progress and Non-Brokered Private Placement of Debenture Units

PharmaCielo Provides Update on Latin American Sales Progress and Non-Brokered Private Placement of Debenture Units

PharmaCielo is actively working with, and has recently shipped product to, established companies in Argentina, Brazil, Colombia and Paraguay. The Company's sales and technical teams are providing support to these customers as they conduct testing and advance product registrations using PharmaCielo APIsi, to market. TORONTO and RIONEGRO... Read More...
PharmaCielo Completes Initial Tranche of Non-Brokered Private Placement of Debenture Units

PharmaCielo Completes Initial Tranche of Non-Brokered Private Placement of Debenture Units

All amounts expressed in Canadian dollars unless otherwise noted TORONTO and RIONEGRO, Colombia, Dec. 31, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), is pleased... Read More...
PharmaCielo Announces $15.0 Million Non-Brokered Private Placement of Debenture Units

PharmaCielo Announces $15.0 Million Non-Brokered Private Placement of Debenture Units

All amounts expressed in Canadian dollars unless otherwise noted TORONTO and RIONEGRO, Colombia, Dec. 22, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today ann... Read More...
PharmaCielo Receives Confirmation of Colombian Phytotherapeutics GMP Certification

PharmaCielo Receives Confirmation of Colombian Phytotherapeutics GMP Certification

GMPi certification has been confirmed by INVIMA.The certification covers Phytotherapeutics manufactured with PharmaCielo´s extracts and proprietary cultivars.PharmaCielo’s Processing and Extraction Centre – the largest in Colombia and one of the largest globally – has been in compliance with EU-GMPii guidelines since February 2021 and the... Read More...
PharmaCielo Announces the Appointment of Cannabis Industry Veterans Bob DeGabrielle and Will Nicholas to the Company's Board

PharmaCielo Announces the Appointment of Cannabis Industry Veterans Bob DeGabrielle and Will Nicholas to the Company’s Board

Mr. DeGabrielle was an early entrepreneur and executive in the U.S. cannabis industry; he founded and owns Los Sueños Farms LLC, the largest outdoor grow in North America, which he recently agreed to sell to Curaleaf, Inc. Mr. Nicholas is an experienced finance professional and an early investor in the global cannabis industry; he was o... Read More...
PharmaCielo Announces Q2-2021 Financial Results and Appointment of Bill Petron as CEO

PharmaCielo Announces Q2-2021 Financial Results and Appointment of Bill Petron as CEO

On track for Revenue growth in the back half of fiscal 2021, as recently signed sales agreements translate into higher volumes. Generated early revenue from more than ten countries in the quarter. Bill Petron, the Company's Chairman and a global operations and cannabis veteran, has been appointed Chief Executive Officer of PharmaCielo. ... Read More...
PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Player in Brazil

PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Player in Brazil

TORONTO and RIONEGRO, Colombia, Aug. 4, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has signed a sales agreement (the "Agreement") with a cannabis-fo... Read More...
PharmaCielo Announces Election of Directors

PharmaCielo Announces Election of Directors

Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. TORONTO and RIONEGRO, Colombia, June 10, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of med... Read More...
PharmaCielo Appoints Experienced Cannabis Executive Ian D. Atacan as Chief Financial Officer

PharmaCielo Appoints Experienced Cannabis Executive Ian D. Atacan as Chief Financial Officer

TORONTO, Canada and RIONEGRO, Colombia, May 31, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO), (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that experienced financial and cannabis executive Ian D. Atacan ... Read More...
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2021

PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2021

Recurring orders during Q1 2021 supported 31% Revenue growth compared to Q1 2020. Strong first quarter growth in demand for PharmaCielo's products, demonstrated by increased volume and repeat sales of CBD isolate and more complex products such as Broad-Spectrum Distillate. Continued growth in interest from potential customers in initia... Read More...
PharmaCielo Announces Bill Petron, a Global Operations and Cannabis Veteran, to Stand for Election as a Nominee for Chairman of the Board

PharmaCielo Announces Bill Petron, a Global Operations and Cannabis Veteran, to Stand for Election as a Nominee for Chairman of the Board

Mr. Petron has a diverse and successful background scaling global manufacturing, logistics and medical cannabis operations. Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. Current Chairman, Simon Langelier, has decided not to sta... Read More...
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2020

PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2020

FY 2020 Revenue of $2.7 million compared to $0.8 million in FY 2019. Achieved key milestones foundational to future commercial success: Completed one of the world's largest processing and extraction complexes1, introduced a broad cannabinoid product portfolio and began validation of GMP2 and EU-GMP2 standards with potential clients expa... Read More...
PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million

PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All figures are in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, April 7, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and produc... Read More...
PharmaCielo Provides Corporate Update

PharmaCielo Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All figures are in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, March 31, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and produ... Read More...
PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering

PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO and RIONEGRO, Colombia, March 4, 2021 - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), is pleased to announce the pricing of its previously announced overnight marketed offering (the "Offering") of co... Read More...
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

Shipped to existing Customer with operations in the U.K. and the E.U. THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed and... Read More...
PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

TORONTO, Dec. 18, 2020 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. today announced that the company has expanded investor relations support capacity with the appointment of Caroline Lenardon to provi... Read More...
PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market

PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market

Alliance with AssuredTrans Inc. will enable PharmaCielo to provide up-front independent laboratory analysis and insurance of its recently expanded product portfolio to potential customers in the U.S., beginning in 2021 Former congressman notes alliance enables U.S. customers to have confidence in the purity and quality of PharmaCielo's ... Read More...
PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario

PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario

Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales pipeline. TORONTO and RIONEGRO, Colombia... Read More...
PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List

PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List

TORONTO, Dec. 3, 2020 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), commends the United Nations Commission on Narcotic Drugs (CND) for its historic decision... Read More...
PharmaCielo Announces Grant of Stock Options

PharmaCielo Announces Grant of Stock Options

TORONTO and RIONEGRO, Colombia, Dec. 2, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), today announced that the board of directors of the Company approved... Read More...
PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020

PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020

Effective December 1, Henning von Koss has been named CEO of PharmaCielo, replacing departing CEO David Attard. Successful achievement of Q3 operational milestones: Processing and Extraction Centre ("PEC") construction completed – one of largest current extraction footprints1 globally; expanded product portfolio launched. Plan to initi... Read More...
PharmaCielo Ltd. Announces New Leadership

PharmaCielo Ltd. Announces New Leadership

David Attard and Board of Directors reach mutual agreement under which David will step down as Chief Executive Officer and PharmaCielo board member, effective December 1st, 2020. Henning von Koss, currently President and a member of PharmaCielo's Board of Directors, formerly with Bayer and 30-year career as senior executive with operati... Read More...
PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation

PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO and RIONEGRO, Colombia, Nov. 25, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: P... Read More...
PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement

PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor – Reaches 2021 Agreement

Including Initial Shipment, PharmaCielo will deliver total 1,000 kg of product to Customer – with revenue and cash flow reflected in 2020; interim 2021 sales agreement reached for continued Q1 volume and revenue.Relationship adds U.K. and additional E.U. exposure to PharmaCielo's current commercial relationships in the U.S., Germany, Swit... Read More...
PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results

PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results

TORONTO and RIONEGRO, Colombia, Nov. 12, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, November 30th... Read More...
Coming Soon.
IndexLast% Change
S&P 5003,693.23--
Euro STOXX 503,344.010.14%Negative
FTSE 1006,963.290.79%Negative
Nikkei 22526,431.552.66%Negative

Delayed data (1h)
IndexLast% Change
S&P 5003,693.23--
Euro STOXX 503,344.010.14%Negative
FTSE 1006,963.290.79%Negative
Nikkei 22526,431.552.66%Negative


Share this page